AzTrials
AzTrials

Overactive Bladder (OAB)Phase 4PILLARNCT02216214

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

A Phase 4 study testing Mirabegron in people with Overactive Bladder (OAB), run by Astellas Pharma Global Development, Inc. at 120 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Overactive Bladder (OAB)
What is being tested?
Mirabegron
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
888 participants
Where
120 sitesin 2 countries
Study dates
7 Oct 2014to 2 Jan 2018
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Subject is willing and able to complete the micturition diary and questionnaires correctly.
  • Subject has symptoms of wet overactive bladder (OAB) (urinary frequency and urgency with incontinence) for greater than or equal to 3 months prior to Screening.
  • Subject agrees not to participate in another interventional study from the time of screening until the final study visit.
  • Inclusion Criteria assessed after placebo run-in period at Visit 3 (Baseline):
  • Subject continues to meet all inclusion criteria of Visit 1.
  • Subjects must experience at least one incontinence episode in the placebo run-in period based on the 3-day micturition diary.
  • Subject must experience at least 3 episodes of urgency (grade 3 or 4) based on the 3-day micturition diary.
  • Subject must experience an average of greater than or equal to 8 micturitions/day based on the 3-day micturition diary.

Who cannot join

  • Subject has ongoing symptoms suggestive of bladder outlet obstruction (BOO) or history of BOO that is currently not well controlled.
  • Subject has Post-Void Residual Volume (PVR) greater than 150 mL.
  • Subject has neurogenic bladder or neurological dysfunction or injury which could affect the lower urinary tract or nerve supply.
  • Subject has significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the Investigator (for female subjects confirmed by a cough provocation test). Subjects with a history of stress incontinence that is currently treated (e.g. remote history of surgery for stress incontinence) may be included as long as they pass cough provocation test.
  • Subject has an indwelling catheter or practices intermittent self-catheterization.
  • Subject has evidence of Urinary Tract Infection (UTI). Urine culture and sensitivity will be performed for positive leukocytes, or nitrites, or turbidity, or at the investigator's discretion and will be confirmed with a culture greater than 100,000 cfu/mL. If a subject has a UTI at Screening (Visit 1), the subject can be rescreened after successful treatment of the UTI (confirmed by a laboratory result of negative urine culture).
Show all 31Show fewer
  • Subject has a chronic inflammatory condition such as interstitial cystitis, bladder stones, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs (i.e., within the confines of the pelvis including the bladder and rectum in both sexes and the uterus, ovaries, and fallopian tubes in females; organs of the lower gastrointestinal tract are not necessarily considered pelvic organs as the distal ascending colon, the full transverse colon and proximal portion of the descending colon are in the abdomen).
  • Subject resides in a nursing home.
  • Subject is likely to enter a hospital or nursing home due to medical instability within the next 6 months in the opinion of the Investigator.
  • Subject has received intravesical injection in the past 12 months with botulinum toxin, resiniferatoxin, or capsaicin.
  • Subject has received electro-stimulation therapy for OAB (e.g. sacral nerve stimulation or Percutaneous Tibial Nerve Stimulation [PTNS]).
  • Subject began or has changed a bladder training program or pelvic floor exercises less than 30 days prior to Screening.
  • Subject has moderate or severe hepatic impairment defined as Child-Pugh Class B or C.
  • Subject has severe renal impairment defined as estimated creatinine clearance less than 29 mL/min determined by Estimated Glomerular Filtration Rate (eGFR, Cockroft-Gault, or MDRD formulae). A subject with end stage renal disease or undergoing dialysis is also not a candidate for the study.
  • Subject has severe uncontrolled hypertension, which is defined as a sitting systolic blood pressure greater than or equal to 180 mmHg and/or diastolic blood pressure greater than or equal to 110 mmHg.
  • Subject has evidence of QT prolongation on electrocardiogram (ECG) defined as QTc greater than 450 msec for males, QTc greater than 470 msec for females or a known history of QT prolongation.
  • Subject has a clinically significant ECG abnormality, as determined by the Investigator.
  • Subject has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 2x upper limit of normal (ULN), or γ-GT greater than 3x ULN and considered clinically significant by the Investigator.
  • Subject has a hypersensitivity to any components of mirabegron, other β-AR agonists, or any of the inactive ingredients.
  • Subject has any clinically significant condition, which in the opinion of the Investigator makes the subject unsuitable for study participation.
  • Subject has been treated with an experimental device within 28 days or received an investigational agent within 28 days or 5 half-lives, whichever is longer, prior to Screening.
  • Subject has a concurrent malignancy or history of any malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully.
  • Subject with current history of alcohol and/or drug abuse.
  • Subject is using prohibited medications which cannot be stopped safely during the period.
  • Subject has stopped, started or changed the dose of a restricted medication within the last 30 days prior to Screening.
  • Subject is involved in the conduct of the study as an employee of the Astellas group, third party associated with the study, or the study site team.
  • Subject has previously received mirabegron.
  • Exclusion Criteria assessed after placebo run-in period at Visit 3 (Baseline):
  • Subject fulfills any exclusion criteria of Visit 1 (subject does not need to repeat screening assessments [PVR, cough provocation test, chemistry/hematology/urinalysis]).
  • Subject was non-compliant during 2-week placebo run-in period, defined as taking less than 80% or greater than 120% of study medication.
  • Subject has any systolic blood pressure measurement > 180 mmHg or diastolic blood pressure measurement > 110 in the 3-day diary or during the baseline visit.

Trial locations and contacts

120 sites in 2 countries.

120 sites in 2 countries

United States103 sites
  • Site US00067

    Akron, Ohio, 44313

  • Site US00140

    Albuquerque, New Mexico, 87102

  • Site US00176

    Anaheim, California, 92801

  • Site US00009

    Anchorage, Alaska, 99503

  • Site US00025

    Annapolis, Maryland, 21401

  • Site US00104

    Augusta, Kansas, 67010

  • Site US00175

    Austin, Texas, 78705

  • Site US00048

    Beverly Hills, California, 90211

  • Site US00142

    Beverly Hills, California, 90212

  • Site US00159

    Billings, Montana, 59102

  • Site US00041

    Boise, Idaho, 83642

  • Site US00032

    Bristol, Tennessee, 37620

  • Site US00091

    Brockton, Massachusetts, 02301

  • Site US00016

    Brooklyn, New York, 11215

  • Site US00064

    Brooksville, Florida, 34601

  • Site US00153

    Charlotte, North Carolina, 28209

  • Site US00154

    Chattanooga, Tennessee, 37421

  • Site US00050

    Cincinnati, Ohio, 45249

  • Site US00095

    Cleveland, Ohio, 44109

  • Site US00026

    Colorado Springs, Colorado, 80907

  • Site US00132

    Concord, North Carolina, 28025

  • Site US00080

    Coral Gables, Florida, 33134

  • Site US00002

    DeBary, Florida, 32713

  • Site US00001

    DeLand, Florida, 32720

  • Site US00017

    DeLand, Florida, 32720

  • Site US00039

    Denver, Colorado, 80220

  • Site US00004

    Denver, Colorado, 80239

  • Site US00113

    East Brunswick, New Jersey, 08816

  • Site US00018

    Edgewater, Florida, 32132

  • Site US00024

    Edina, Minnesota, 55435

  • Site US00085

    Fargo, North Dakota, 58103

  • Site US00027

    Fleming Island, Florida, 32003

  • Site US00053

    Franklin, Tennessee, 37064

  • Site US00056

    Grand Rapids, Michigan, 49503

  • Site US00122

    Greensboro, North Carolina, 27403

  • Site US00060

    Greenwood, Indiana, 46143

  • Site US00150

    Hawaiian Gardens, California, 90716

  • Site US00151

    Hialeah, Florida, 33016

  • Site US00131

    Houston, Texas, 77030

  • Site US00066

    Huntsville, Alabama, 35801

  • Site US00174

    Hurst, Texas, 76054

  • Site US00046

    Jeffersonville, Indiana, 47130

  • Site US00179

    Jupiter, Florida, 33458

  • Site US00003

    Kalamazoo, Michigan, 49009

  • Site US00057

    Kissimmee, Florida, 34744

  • Site US00172

    Lake Charles, Louisiana, 70601

  • Site US00076

    Lakeland, Florida, 33805

  • Site US00014

    Las Vegas, Nevada, 89148

  • Site US00063

    Little Rock, Arkansas, 72120

  • Site US00081

    Little Rock, Arkansas, 72205

  • Site US00112

    Los Angeles, California, 90017

  • Site US00034

    Los Angeles, California, 90027

  • Site US00062

    Madison, Wisconsin, 53715

  • Site US00084

    Mentor, Ohio, 44094

  • Site US00037

    Miami, Florida, 33135

  • Site US00029

    Miami, Florida, 33144

  • Site US00042

    Miami, Florida, 33173

  • Site US00015

    Middleburg Heights, Ohio, 44130

  • Site US00148

    Mobile, Alabama, 36608

  • Site US00082

    Moncks Corner, South Carolina, 29461

  • Site US00162

    Mt. Pleasant, South Carolina, 29464

  • Site US00010

    Murrieta, California, 92562

  • Site US00052

    Nashville, Tennessee, 37211

  • Site US00006

    New Bedford, Massachusetts, 02740

  • Site US00111

    New Brunswick, New Jersey, 08901

  • Site US00040

    New London, Connecticut, 06320

  • Site US00170

    Newport News, Virginia, 23606

  • Site US00105

    Newton, Kansas, 67114

  • Site US00070

    Norfolk, Nebraska, 68701

  • Site US00086

    Norfolk, Virginia, 23502

  • Site US00102

    Norman, Oklahoma, 73069

  • Site US00007

    North Miami, Florida, 33161

  • Site US00045

    Overland Park, Kansas, 66202

  • Site US00180

    Pittsburgh, Pennsylvania, 15236

  • Site US00021

    Pompano Beach, Florida, 33060

  • Site US00035

    Port Orange, Florida, 32129

  • Site US00103

    Portland, Oregon, 97239

  • Site US00161

    Raleigh, North Carolina, 27609

  • Site US00093

    Saginaw, Michigan, 48604

  • Site US00044

    Salt Lake City, Utah, 84107

  • Site US00036

    Salt Lake City, Utah, 84124

  • Site US00068

    San Antonio, Texas, 78209

  • Site US00071

    San Antonio, Texas, 78229

  • Site US00100

    San Antonio, Texas, 78229

  • Site US00135

    San Diego, California, 92117

  • Site US00139

    San Diego, California, 92120

  • Site US00144

    Santa Maria, California, 93454

  • Site US00137

    Sartell, Minnesota, 56377

  • Site US00005

    Savannah, Georgia, 31406

  • Site US00167

    Seattle, Washington, 98150

  • Site US00075

    St. Petersburg, Florida, 33709

  • Site US00083

    Stanford, California, 94305

  • Site US00098

    Tacoma, Washington, 98405

  • Site US00099

    Tampa, Florida, 33606

  • Site US00020

    Tucson, Arizona, 85715

  • Site US00019

    Tucson, Arizona, 85745

  • Site US00090

    Washington D.C., District of Columbia, 20010

  • Site US00145

    Watertown, Massachusetts, 02472

  • Site US00134

    West Des Moines, Iowa, 50266

  • Site US00023

    West Jordan, Utah, 84088

  • Site US00043

    Williamsville, New York, 14221

  • Site US00165

    Wilmington, North Carolina, 28401

  • Site US00166

    Winston-Salem, North Carolina, 27103

Other trials in United States

Canada17 sites
  • Site CA00155

    Brampton, Ontario, L6T 4S5

  • Site CA00123

    Corunna, Ontario, N0N1G0

  • Site CA00130

    Edmonton, Alberta, T5G 0B7

  • Site CA00169

    Greater Sudbury, Ontario, P3E 3Z9

  • Site CA00126

    Hamilton, Ontario, L8N 4A6

  • Site CA00164

    Lévis, Quebec, G6W 0M6

  • Site CA00118

    London, Ontario, N6A 4V2

  • Site CA00158

    Montreal, Quebec, H2Y 1S1

  • Site CA00073

    Point Claire, Quebec, H9R4S3

  • Site CA00106

    Point Claire, Quebec, H9R4S3

  • Site CA00129

    Québec, G1S2L6

  • Site CA00160

    Québec, G1X 0B6

  • Site CA00116

    Sarnia, Ontario, N7T4X3

  • Site CA00156

    Sherbrooke, Quebec, J1H 1Z1

  • Site CA00061

    Sherbrooke, Quebec, J1H5N2

  • Site CA00168

    Toronto, Ontario, M4S 1Y2

  • Site CA00074

    Vancouver, British Columbia, V6J1S3

Other trials in Canada

About this study

Official title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.

Being tested
Mirabegron, Placebo
Keywords
Urinary Incontinence, Mirabegron, Overactive Bladder
Medical subject headings
Urinary Bladder, Overactive, Urinary Incontinence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MirabegronDrug

    Also called YM178, Myrbetriq

    oral tablet

  • PlaceboDrug

    oral tablet

Study groups in NCT02216214
Study groupRoleWhat they receive
PlaceboPlacebo comparatorParticipants received placebo to match mirabegron at an initial dose of 25 mg and may have been increased to 50 mg of matching placebo based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
Receives: Drug: Placebo
MirabegronExperimentalParticipants received mirabegron at an initial dose of 25 mg and may have been increased to 50 mg mirabegron after 4 weeks or 8 weeks based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
Receives: Drug: Mirabegron

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline to End of Treatment (EOT) in Mean Number of Micturitions Per 24 Hours

    A micturition was defined as any voluntary act of passing urine (excluding incontinence only episodes). The mean number of micturitions per 24 hours was calculated as the average number of times a participant urinated per day during the 3-day micturition diary period.

    Measured: Baseline and EOT (up to 12 weeks)

  2. Change From Baseline to EOT in Mean Number of Incontinence Episodes Per 24 Hours

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours was calculated as the average number of times a participant recorded an incontinence episode per day during the 3-day micturition diary period.

    Measured: Baseline and EOT (up to 12 weeks)

Secondary outcomes (24)
  1. Change From Baseline to EOT in Mean Volume Voided Per Micturition

    The mean volume voided per micturition during 3 days of the 3-day micturition diary period.

    Measured: Baseline and EOT (up to 12 weeks)

  2. Change From Baseline to EOT in Overactive Bladder Questionnaire (OAB-q): Symptom Bother Score

    The OAB-q is a self-reported questionnaire with 33 questions relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consists of 8 questions, rated on a 6-point Likert scale (1 through 6). The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicated an improvement.

    Measured: Baseline and EOT (up to 12 weeks)

  3. Change From Baseline to EOT in OAB-q: Health Related Quality of Life (HRQL) Total Score

    The OAB-q is a self-reported questionnaire with 33 questions relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. The total score was calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.

    Measured: Baseline and EOT (up to 12 weeks)

  4. Change From Baseline to EOT in Patient Perception of Bladder Condition (PPBC)

    The PPBC is a validated, global assessment tool using a 6-point Likert scale that asks participants to rate their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems. A higher score indicated a worse perception of bladder condition.

    Measured: Baseline and EOT (up to 12 weeks)

  5. Change From Baseline to EOT in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours

    Urgency was defined as a complaint of a sudden, compelling desire to pass urine, which is difficult to defer. An urgency episode was defined as any micturition or incontinence episode with a severity of grade 3 or 4, assessed by participants based on the PPIUS, where 0 = No urgency; 1 = Mild urgency; 2 = Moderate urgency, could delay voiding a short while; 3 = Severe urgency, could not delay voiding; 4 = Urge incontinence, leaked before arriving to the toilet. The mean number of urgency episodes (grade 3 and/or 4) per 24 hours was calculated as the average number of times a participant recorded an urgency episode (grade 3 and/or 4) with or without incontinence per day during the 3-day micturition diary period.

    Measured: Baseline and EOT (up to 12 weeks)

  6. Change From Baseline to EOT in Mean Number of Urgency Incontinence Episodes Per 24 Hours

    An urgency incontinence episode was defined as the involuntary leakage of urine accompanied by or immediately preceded by urgency. The mean number of urgency episodes was calculated as the average number of times a participant recorded an urgency incontinence episode per day during the 3-day micturition diary period.

    Measured: Baseline and EOT (up to 12 weeks)

  7. Change From to EOT in Mean Number of Nocturia Episodes Per 24 Hours

    A nocturia episode was defined as waking at night one or more time to void (i.e., any voiding associated with sleep disturbance between the date/time the participant goes to bed with the intention to sleep until the date/time the participant gets up in the morning with the intention to stay awake). A night time episode of incontinence only is not considered a nocturia episode. The mean number of nocturia episodes per 24 hours was calculated as the average number of times a participant recorded a nocturia episode per day during the 3-day micturition diary period.

    Measured: Baseline and EOT (up to 12 weeks)

  8. Change From Baseline to EOT in Barthel Index of Daily Living Score

    The Barthel Index consists of 10 items that measure a person's daily functioning; specifically the activities of daily living and mobility. The total possible score ranges from 0 to 20, with lower scores indicating increased disability.

    Measured: Baseline and EOT (up to 12 weeks)

  9. Change From Baseline to EOT in Vulnerable Elder Survey-13 (VES-13) Score

    The VES-13 is a simple function-based tool for screening community-dwelling populations to identify older persons at risk for health deterioration. The VES-13 considers age, self-related health, limitation in physical function, and functional disabilities. The total possible score ranges from 0 to 10, with higher scores indicating increased disability.

    Measured: Baseline and EOT (up to 12 weeks)

  10. Change From Baseline to EOT in PPIUS

    The PPIUS is a 5-point categorical scale used by participants to rate the degree of associated urgency for each micturition and/or incontinence episode they experienced. categories include: 0 - No urgency, I felt no need to empty my bladder, but did so for other reasons; 1 - Mild urgency, I could postpone voiding as long as necessary, without fear of wetting myself; 2 - Moderate urgency, I could postpone voiding for a short while, without fear of wetting myself; 3 - Severe urgency, I could not postpone voiding, but had to rush to the toilet in order not to wet myself; 4 - Urge incontinence, I leaked before arriving at the toilet. Scores were recorded in the micturition diary.

    Measured: Baseline and EOT (up to 12 weeks)

  11. Change From Baseline to EOT in OAB-q HRQL Subscale Scores

    The OAB-q is a self-reported questionnaire with 33 questions relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. The Coping score has 8 items, the Concern score has 7 items, the Sleep and Social score has 5 items each. Each subscale score was calculated by adding each score's items and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicated an improvement.

    Measured: Baseline and EOT (up to 12 weeks)

  12. Change From Baseline to EOT in Treatment Satisfaction Visual Analog Scale (TS-VAS)

    The TS-VAS is a visual analog scale that asks participants to rate their satisfaction with the treatment by placing a vertical mark on a line that runs from 0 (No, not at all) to 100 (Yes, completely).

    Measured: Baseline and EOT (up to 12 weeks)

  13. Change From Baseline to EOT in University of Alabama, Birmingham - Life Space Assessment (UAB-LSA)

    The UAB-LSA measures mobility in terms of the spatial extent of a person's life. Life space is defined based upon the distance a person routinely travels to perform activities over this time frame. The UAB-LSA includes determining how far and how often the person leaves his or her place of residence and the degree of independence the person has. Each level of life space represents a distance further from the room where one sleeps: 0 - Mobility limited to the room where one sleeps; 1 - Mobility limited to within one's dwelling; 2 - Mobility limited to the space just proximal to one's personal living space (for instance, a porch, patio, or yard just outside the home or hallway outside of an apartment); 3 - Mobility limited to one's neighborhood; 4 - Mobility limited to one's town; 5 - Mobility outside one's town. The total scores ranges from 0-120, where a higher score indicates greater mobility.

    Measured: Baseline and EOT (up to 12 weeks)

  14. Change From Baseline in Number of Incontinence Episodes Reported During 3-Day Diary Prior to Each Visit

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. The number of incontinence episodes were calculated as the total number of the incontinence episodes recorded during the 3-day micturition diary period.

    Measured: Baseline and Weeks 4, 8 and EOT (up to 12 weeks)

  15. Change From Baseline in Number of Pads During 3-Day Diary Prior to Each Visit

    The number of pads were calculated as the number of times a participant records a new pad used during the 3-day micturition diary period. No data were collected for the number of pads used due to a failure in the programming of the diary used for data collection.

    Measured: Baseline and EOT (up to 12 weeks)

  16. Percentage of Participants Who Achieved Micturition Frequency Normalization

    Participants who achieved micturition frequency normalization were defined as participants who had at least 8 micturitions per 24 hours at baseline and less than 8 micturitions per 24 hours post-baseline.

    Measured: End of treatment (up to 12 weeks)

  17. Percentage of Participants With 50% Reduction in Mean Number of Incontinence Episodes Per 24 Hours

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. Participants with 50% reduction in mean number of incontinence episodes per 24 hours were defined as participants with at least 50% decrease from baseline in mean number of incontinence episodes per 24 hours during the treatment period at each visit.

    Measured: End of treatment (up to 12 weeks)

  18. Percentage of Participants With Zero Incontinence Episodes Per 24 Hours

    An incontinence episode was defined as the complaint of any involuntary leakage of urine. Participants with zero incontinence episodes per 24 hours were defined as participants who had no incontinence episodes per 24 hours during the treatment period at each visit.

    Measured: End of treatment (up to 12 weeks)

  19. Percentage of Participants With ≥ 10-Point Improvement From Baseline in OAB-q HRQL Subscales

    The OAB-q is a self-reported questionnaire with 33 questions relating to symptom bother and health-related quality of life (HRQoL). The HRQoL portion consists of 25 HRQoL items comprising 4 HRQoL subscales (Coping, Concern, Sleep, and Social Interaction), each item was scored 1-6. The Coping score has 8 items, the Concern score has 7 items, the Sleep and Social score has 5 items each. Each subscale score was calculated by adding each score's items and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. Participants with ≥ 10-point improvement from baseline in OAB-q HRQL subscales were defined as participants with at least 10-point improvement from baseline in OAB-q Subscales at each visit.

    Measured: End of treatment (up to 12 weeks)

  20. Percentage of Participants With ≥ 1-Point Improvement From Baseline in PPBC

    The PPBC is a validated, global assessment tool using a 6-point Likert scale that asks participants to rate their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems. A higher score indicated a worse perception of bladder condition. Participants with ≥ 1-point improvement from baseline in PPBC were defined as participants with at least 1-point improvement from baseline in PPBC at each visit.

    Measured: End of treatment (up to 12 weeks)

  21. Percentage of Participants Major (≥ 2-Point) Improvement From Baseline in PPBC

    The PPBC is a validated, global assessment tool using a 6-point Likert scale that asks participants to rate their subjective impression of their current bladder condition. Participants assessed their bladder condition using this scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems. A higher score indicated a worse perception of bladder condition. Participants with ≥ 2-point improvement from baseline in PPBC were defined as participants with at least 1-point improvement from baseline in PPBC at each visit.

    Measured: End of treatment (up to 12 weeks)

  22. Number of Participants With Adverse Events (AEs)

    Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. AEs were considered as serious if resulted in in death, was life-threatening resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly or birth defect, required inpatient hospitalization or led to prolongation of hospitalization and other medically important events.

    Measured: From first dose of study drug up to 30 days after last dose of study drug (up to 13 weeks)

  23. Change From Baseline to EOT in Montreal Cognitive Assessment (MoCA) Score

    The MoCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The total possible score is 30 points, with lower scores indicating worse cognitive function.

    Measured: Baseline and EOT (up to 12 weeks)

  24. Change From Baseline in Post-void Residual Volume (PVR)

    PVR was assessed by ultrasonography or bladder scan.

    Measured: Baseline and EOT (up to 12 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2014 (estimated)
  2. Study start7 Oct 2014
  3. Primary completion29 Nov 2017
  4. Study completion2 Jan 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
888 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02216214
Sponsor's protocol ID
178-MA-1005
Acronym
PILLAR
Status last verified
Oct 2024
First submitted
12 Aug 2014
Last updated
22 Nov 2024
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Publications

  • Herschorn S, Staskin D, Schermer CR, Kristy RM, Wagg A. Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients >/= 65 years with Overactive Bladder-Wet. Drugs Aging. 2020 Sep;37(9):665-676. doi: 10.1007/s40266-020-00783-w.

    PubMed 32725584
  • Griebling TL, Campbell NL, Mangel J, Staskin D, Herschorn S, Elsouda D, Schermer CR. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020 Mar 18;20(1):109. doi: 10.1186/s12877-020-1474-7.

    PubMed 32183741

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Mirabegron in people with Overactive Bladder (OAB), run by Astellas Pharma Global Development, Inc. at 120 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 120 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Feb 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to End of Treatment (EOT) in Mean Number of Micturitions Per 24 Hours (time frame: Baseline and EOT (up to 12 weeks)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02216214, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in